Trial | Treatment history | Number of patients treated—suffering from G4 HCV | Patient characteristics | Treatment | SVR rate |
---|---|---|---|---|---|
Marcellin et al16 | Naïve | 317 | 51 bridging fibrosis/cirrhosis 214 no bridging fibrosis/cirrhosis | PEG-IFN α2a or PEG-IFN α2b+RBV (clinician discretion) | 27.5% 41% |
El Raziky et al17 | Naïve | 3718 | 6.3% cirrhotic 5.9% cirrhotic | PEG-IFN α2a+RBV (n=1985) PEG-IFN α2b+RBV (n=1733) | 59.6% 53.9% |
Kamal et al19 | Naïve | 358 | Highly selected, few cirrhotic | Virus negative week 4–24 weeks PEG-IFN α2b Virus negative week 12–36 weeks PEG-IFN α2b Virus positive week 4+12–48 weeks PEG-IFN α2b | 86% 76% 56% |
Poynard et al22 | Experienced | 68 | Fibrosis stage 2, 3 and 4 | PEG-IFN α2b+RBV | 28% |
PEG-IFN pegylated interferon; RBV ribavirin; SVR sustained virologic response.